Drug Type Immune cell therapy |
Synonyms- |
Target- |
Action- |
Mechanism Cell replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Breast Cancer | Phase 2 | United States | 03 Jul 2014 | |
Kidney Neoplasms | Phase 2 | United States | 03 Jul 2014 | |
MAGE-A3 Positive Muscle Invasive Bladder Carcinoma | Phase 2 | United States | 03 Jul 2014 | |
Metastatic melanoma | Phase 2 | United States | 03 Jul 2014 | |
Neoplasm Metastasis | Phase 2 | United States | 03 Jul 2014 | |
Uterine Cervical Cancer | Phase 2 | United States | 03 Jul 2014 |
Phase 1/2 | 3 | Aldeskeukin+Mesna+fludarabine+cyclophosphamide+aldesleukin+MAGE-A3- A1 transduced peripheral blood lymphocytes (PBL) (Anti-MAGE-A3 A1 TCR PBL 1x10^9 Cells + Interleukin-2 (IL-2)) | (mnzjhlgadv) = xjzsagnycs jvuyzxfuff (fxnrpyplxx, xgeioirhgl - bonjdyrsme) View more | - | 05 Jun 2019 | ||
Aldeskeukin+Mesna+fludarabine+cyclophosphamide+aldesleukin+MAGE-A3- A1 transduced peripheral blood lymphocytes (PBL) (Anti-MAGE-A3 A1 TCR PBL 1x10^8 Cells + Interleukin-2 (IL-2)) | (mnzjhlgadv) = zaytniserl jvuyzxfuff (fxnrpyplxx, bbjczjcnkz - uwqhluoxur) View more |